Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029 [Yahoo! Finance]
Karyopharm Therapeutics Inc. (KPTI)
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.karyopharm.com/investor-relations
Company Research
Source: Yahoo! Finance
– Issues New $100.0 Million Senior Secured Term Loan due in 2028 – – Repays Principal Portion and Amends Royalty Agreement with HealthCare Royalty – NEWTON, Mass. May 8, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced today that it has entered into a series of financing transactions that will extend the Company's debt maturities into 2028 and 2029, well beyond the Company's planned Phase 3 data readouts in 2025. "We are extremely pleased to have accomplished several important objectives for Karyopharm and our shareholders with this refinancing. We successfully strengthened our balance sheet by extending the maturity of the vast majority of our debt obligations well beyond the planned readouts and potential approvals of our three ongoing Phase 3 programs," said Richard Paulson , President and Chief Executive Officer of Karyopharm. "With the demonstrated strong commitment from
Show less
Read more
Impact Snapshot
Event Time:
KPTI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KPTI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KPTI alerts
High impacting Karyopharm Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
KPTI
News
- Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- Karyopharm Therapeutics (KPTI) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare ConferencePR Newswire
KPTI
Earnings
- 5/8/24 - Beat
KPTI
Analyst Actions
- 5/9/24 - HC Wainwright
KPTI
Sec Filings
- 5/14/24 - Form 8-K
- 5/8/24 - Form 10-Q
- 5/8/24 - Form 8-K
- KPTI's page on the SEC website